Related Experiment Video
Updated: Dec 17, 2025

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Preclinical contraceptive development for men and women
Daniel S Johnston1, Erwin Goldberg2
1Contraception Research Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Abstract:
This manuscript endeavors to present research considerations for the preclinical development of non-hormonal contraceptives. Topics include (1) how advances in genomics and bioinformatics impact the identification of novel targets for non-hormonal contraception, (2) the importance of target validation prior to investment in a contraceptive development campaign, (3) considerations on targeting gametogenesis vs gamete maturation/function, (4) how targets from the male reproductive system are expanding women's options for 'on demand' contraception, and (5) some emerging non-hormonal methods that are not based on a specific molecular target. Also presented are ideas for developing a pipeline of non-hypothalamic-pituitary-gonadal-acting contraceptives for men and women while balancing risk and innovation, and our perspective on the pros and cons of industry and academic environments on contraceptive development. Three product development programs are highlighted that are biologically interesting, innovative, and likely to influence the field of contraceptive development in years to come.
Insights
This research explores preclinical development for non-hormonal contraceptives, focusing on novel target identification and validation. It discusses male reproductive targets expanding options and emerging methods for future contraceptive development.
Area of Science:
- Reproductive biology and pharmacology
- Genomics and bioinformatics in drug discovery
Background:
- Advancements in genomics and bioinformatics are crucial for identifying novel targets in non-hormonal contraceptive research.
- Target validation is essential before significant investment in contraceptive development campaigns.
Purpose of the Study:
- To present research considerations for preclinical non-hormonal contraceptive development.
- To explore innovative strategies for developing a pipeline of contraceptives targeting both male and female reproductive systems.
- To highlight promising product development programs influencing the field.
Main Methods:
- Review of current research in genomics, bioinformatics, and reproductive biology.
- Analysis of target validation strategies for contraceptive development.
- Discussion of emerging non-hormonal contraceptive methods and product development programs.
Main Results:
- Genomics and bioinformatics facilitate novel non-hormonal contraceptive target discovery.
- Male reproductive system targets offer new 'on demand' contraceptive options for women.
- Emerging methods expand contraceptive approaches beyond specific molecular targets.
Conclusions:
- Strategic preclinical development is key for advancing non-hormonal contraceptives.
- A balanced approach considering risk and innovation is needed for pipeline development.
- Innovative research programs are poised to significantly impact future contraceptive options.
More Related Videos
Related Concept Videos
Preclinical Development: Overview
Birth Control Methods
Clinical Trials: Overview
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Infertility in Males
Clinical Trials
There are four phases in a clinical trial. A phase one...

